Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice. (Q46199321)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

review article

1 reference

title

Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

author name string

Christoph Kapitza

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

Jeremy Pettus

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

Tim Heise

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

language of work or name

English

0 references

publication date

23 June 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

Current Medical Research and Opinion

21 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

page(s)

1821-1831

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

Insulin stacking versus therapeutic accumulation: understanding the differences.

21 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Basal insulins: Pharmacological properties and patient perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Evolution of insulin development: focus on key parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Evolution of insulin: from human to analog

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Contribution of the dawn phenomenon to the fasting and postbreakfast hyperglycemia in type 1 diabetes treated with once-nightly insulin glargine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Nocturnal blood glucose and IGFBP-1 changes in type 1 diabetes: Differences in the dawn phenomenon between insulin regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

The interpretation of glucose clamp studies of long-acting insulin analogues: from physiology to marketing and back.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Steady state is reached within 2-3 days of once-daily administration of degludec, a basal insulin with an ultralong duration of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

No evidence for accumulation of insulin glargine (LANTUS): a multiple injection study in patients with Type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin glargine metabolite 21(A) -Gly-human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Exercise management in type 1 diabetes: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A double-blind, randomized, dose-response study investigating the pharmacodynamic and pharmacokinetic properties of the long-acting insulin analog detemir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Fluctuation and reproducibility of exposure and effect of insulin glargine in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferior

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Basal insulin and cardiovascular and other outcomes in dysglycemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Does insulin glargine increase the risk of cancer compared with other basal insulins?: A French nationwide cohort study based on national administrative databases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin glargine and cancer risk in patients with diabetes: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Low within- and between-day variability in exposure to new insulin glargine 300 U/ml

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New insulin glargine 300 U/ml versus glargine 100 U/ml in Japanese adults with type 1 diabetes using basal and mealtime insulin: glucose control and hypoglycaemia in a randomized controlled trial (EDITION JP 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 1 Diabetes: A Randomized, Phase 3a, Open-Label Clinical Trial (EDITION 4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

One-year sustained glycaemic control and less hypoglycaemia with new insulin glargine 300 U/ml compared with 100 U/ml in people with type 2 diabetes using basal plus meal-time insulin: the EDITION 1 12-month randomized trial, including 6-month exten

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Sustained glycaemic control and less nocturnal hypoglycaemia with insulin glargine 300U/mL compared with glargine 100U/mL in Japanese adults with type 1 diabetes (EDITION JP 1 randomised 12-month trial including 6-month extension).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

New Insulin Glargine 300 U/mL for the Treatment of Type 1 and Type 2 Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Efficacy and Safety of Insulin Degludec 200 U/mL and Insulin Degludec 100 U/mL in Patients with Type 2 Diabetes (Begin: Compare).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A review of the pharmacological properties of insulin degludec and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-ta

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of basal insulin: a meta-analysis of 5 randomized begin trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in i

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/03007995.2017.1335192

10.1080/03007995.2017.1335192

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:28537449 AND SRC:MED&resulttype=core&format=json

21 March 2020

1 reference